Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
The present invention discloses compounds according to Formula I: wherein R 1 is as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment cystic fibrosis by administering a compound of the invention.
1. A method for the treatment of cystic fibrosis, comprising administering to a subject an effective amount of a compound according to Formula I
wherein R 1 is pyrazolyl;
or a pharmaceutically acceptable salt.
2. The method according to claim 1 , wherein the compound is N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide or a pharmaceutically acceptable salt.
3. A method for the treatment of cystic fibrosis, comprising administering to a subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound according to Formula I
wherein R 1 is pyrazolyl;
or a pharmaceutically acceptable salt.
4. The method according to claim 3 , wherein the compound is N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide or a pharmaceutically acceptable salt.
5. A compound according to Formula I
wherein R 1 is pyrazolyl;
or a pharmaceutically acceptable salt.
6. The compound of claim 5 , where the compound is N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide or a pharmaceutically acceptable salt.